LAG-3

This is the latest episode of the free DDW narrated podcast, “Important therapies for the future of immunotherapy”, which covers two articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “Improving quality control for CAR T cell therapies”, and “The importance of LAG-3 to the future of immunotherapy”. The […]

Immutep, a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, has initiated AIPAC-003 (Active Immunotherapy, Eftilagimod Alpha, and Paclitaxel), an integrated Phase II/III trial to evaluate eftilagimod alpha (efti) in combination with paclitaxel for the treatment of metastatic HER2-neg/low breast cancer (MBC).   Regulatory approval has been received in the US […]

Listen to this article on the DDW Podcast: Immutep is working to understand and develop therapeutics that relate to Lymphocyte Activation gene-3 or ‘LAG-3’ which is a cell surface molecule that plays a vital role in regulating the immune system. LAG-3 was discovered by Frederic Triebel, CSO, Immutep, putting the company at the forefront of immunotherapy […]